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patients who reported adverse events in the last 4 weeks, of which, 14.8% experienced 
digestive symptoms, 8.9% with skin allergies, 22.2% with blurred vision, 4.0% with 
liver and kidney damages. CONCLUSIONS: The majority of T2DM patients treated 
with OADs in China had suboptimal glycemic control. The adverse events of OADs 
treatment impose a high disease burden on patients. It underscores the urgent need 
for new therapies in the prevention and management of diabetes.
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OBJECTIVES: To examine the effectiveness of an employer-sponsored, pharmacist-
provided medication therapy management (MTM) program by evaluating changes in 
patient knowledge and clinical outcomes over 1 year in patients with diabetes. 
METHODS: A prospective pre–post longitudinal study. Three 10-question knowledge 
tests were developed collaboratively by an expert panel of clinical pharmacists and 
researchers, as part of the MTM program. Throughout the duration of the program, 
pharmacists administered the tests to City of Toledo employees and their dependents 
with diabetes, at baseline, 6 months and 12 months. The tests were designed to assess 
patients’ understanding of the causes, symptoms, and clinical goals associated with 
diabetes, hypertension, and hyperlipidemia. Based on the test results, pharmacists were 
able to tailor counseling sessions by educating patients based on the questions 
answered incorrectly. Clinical data were simultaneously recorded at 3-month intervals 
over 1 year, and included the following variables: A1c, systolic blood pressure (SBP), 
and diastolic blood pressure (DBP). Data were analyzed with SPSS v16.0 using descrip-
tive statistics, and Wilcoxin tests. RESULTS: One hundred and one patients enrolled 
in the MTM program. Diabetes knowledge improved for 29 patients (58.00%; P < 
0.001) after only 6 months. Hypertension test scores improved for 15 patients (65.22%; 
P < 0.01) after 1 year. Of those patients, reductions in SBP and DBP toward goal were 
seen in 11 (73.33%, P = 0.023) and 15 patients (100%, P = 0.001), respectively. Overall, 
41 patients (56.16%; P = 0.042) reduced their A1c toward goal within 3 months; 22 
patients (59.46%; P = 0.050) were able to decrease their SBP toward goal, whereas 24 
patients (64.86%; P = 0.018) reduced their DPB toward goal after 12 months in the 
program. CONCLUSIONS: This community pharmacy MTM program has effectively 
shown that consistent patient education delivered by a clinical pharmacist can have a 
positive impact on knowledge of disease for patients with diabetes while improving 
clinical outcomes concomitantly.
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OBJECTIVES: To assess and compare the predictive and discriminative performances 
of comorbidity indexes for health-care outcomes and evaluate comorbidity dimension-
ality using psychometric techniques. METHODS: The sample was type 2 diabetes in 
the Medicaid setting from 2003 to 2007. The conceptual framework was based on 
the Aday-Anderson’s Healthcare Utilization model. Four comorbidity indexes targeted 
were the Charlson Comorbidity Index, Elixhauser Index (EI), Chronic Disease Score 
(CDS), and Health-related Quality-of-Life Comorbidity Index (HRQL-CI). Three 
types of outcomes were health-care behaviors, including physician treatment adher-
ence and patient medication adherence, utilization and expenditures. Multiple regres-
sion analyses assessed the predictive performance of comorbidity index. The c statistic 
(the area under the receiver operator curve) evaluated discriminative validity of the 
comorbidity index. Conﬁ rmatory factor analysis identiﬁ ed comorbidity dimensional-
ity. The SASTM, STATATM, and LISRELTM statistical software were utilized. RESULTS: 
A total of 9832 patients were ﬁ nally included, with mean age of approximate 45 years 
and the majority of them was female (73%) and White (52%). The CDS demonstrated 
the best performance in predicting physician treatment adherence and discriminating 
medication adherence behavior. The CDS and HRQL-CI mental aspect index had 
better predictive validity for medication adherence and similar discrimination for 
physician treatment adherence. Diagnosis-driven indexes (e.g., EI) had better perfor-
mances for health-care utilization and expenditures outcomes compared to medica-
tion-based index (CDS). A 7-factor pattern/dimensionality was noticed and it provided 
best model ﬁ t and predictive performance across different health-care outcomes. 
Individual comorbidity dimensions demonstrated differential impacts for a given 
outcome. CONCLUSIONS: The CDS and HRQL-CI mental aspect index served as 
better risk adjustment tools for studying health-care behaviors. Diagnosis-driven 
indexes remained the ﬁ rst choice for health-care utilization and expenditures data. 
Comorbidity index which accounts for comorbidity dimensionality provided better 
risk adjustment and insightful knowledge regarding the impacts of different features 
of comorbidities in predicting patient outcomes.
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OBJECTIVES: To assess the predictors for the initiation of a basal-supported oral 
therapy (BOT) in type 2 diabetics (T2D) under real-life conditions in Germany. 
METHODS: This historical cohort study included T2D who started an oral antidia-
betic drug (OAD) treatment between January 1995 and June 2006 and whose records 
were eligible at least 12 months before and 36 months after OAD initiation. Data 
were extracted from a representative real-life database (IMS® Disease Analyzer). BOT 
initiation was deﬁ ned according to the ATC code of the European Pharmaceutical 
Market Research Association, with A10C2 (NPH insulin) and A10C5 (long-acting 
insulin analogues) prescribed additionally to OADs. The time-dependent rate of T2D 
starting BOT was calculated by use of the Kaplan–Meier method. Univariate and 
multivariate Cox regression analyses were applied to identify predictive associated 
factors. RESULTS: A total of 9028 T2D on initial OAD therapy were included, of 
whom 1450 patients have been switched to BOT during the observational period. The 
probability of BOT initiation was associated with poor metabolic control, midlife age, 
and OAD therapy before insulinization. The combined Cox regression analysis identi-
ﬁ ed three groups of particular importance: group I (hazard ratio [HR] = 2.72; P < 
0.001): HbA1c > 8%, age 51–60 years, and sulfonylurea (SU), alpha-glucosidase 
inhibitor (AGI), or glinide (GLI) as last OAD prescribed, group II (HR = 2.62; P = 
0.032): HbA1c > 8%, age ≤ 50 and pretreatment with at least three OADs, and group 
III (HR = 2.10; P = 0.019): HbA1c > 8%, pretreatment with a combination of at least 
three OADs and SU, AGI, or GLI as last OAD prescribed. The HbA1c threshold of 
7.5% led to comparable results, although only group I reached signiﬁ cance. CON-
CLUSIONS: The probability of BOT initiation for T2D under real-life conditions in 
Germany was associated with poor metabolic control, midlife age, and pretreatment 
with SU, AGI, or GLI. This knowledge may help to identify patients who might beneﬁ t 
from an early initiation of BOT.
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OBJECTIVES: CHOICE is an ongoing prospective, multicountry observational study 
designed to evaluate time to signiﬁ cant treatment change among adults with type 2 
diabetes (T2D) initiating injectable therapy in routine practice, and describing baseline 
characteristics, clinical outcomes, and common adverse events over 24 months. Results 
presented are from 6-month data analyses of the German sample. METHODS: Data 
were collected at initiation of exenatide or insulin, and 3 and 6 months thereafter. 
RESULTS: In Germany, 848 patients (394 exenatide, 454 insulin) were enrolled. 
Multivariate logistic regression indicated that high BMI, hypoglycemia, and high tri-
glyceride levels were associated with exenatide initiation, while increased age, high 
blood glucose levels, and increased frequency of blood glucose monitoring were associ-
ated with insulin initiation. Signiﬁ cant treatment changes were made in 20.7% of 
exenatide-treated and 29.7% of insulin-treated patients; corresponding discontinua-
tion rates of initiated injectable therapy were 15.5% and 4.1%. At 6 months, mean 
(SD) HbA1c change from baseline was −0.8% (1.4%) in the exenatide cohort (baseline 
8.2%) and −1.6% (1.7%) in the insulin cohort (baseline 8.8%). 21.5% of patients 
initiating exenatide achieved an HbA1c of <6.5% and 42.5% of <7.0%. Corresponding 
values for patients initiating insulin were 17.7% and 41.7%, respectively. Mean body 
weight changes were −3.7 kg in the exenatide cohort and +0.9 kg in the insulin cohort. 
Gastrointestinal symptoms and hypoglycemic episodes were reported by 19.7% and 
2.3% of patients in the exenatide cohort, respectively, and 2.5% and 11.3% of 
patients in the insulin cohort. CONCLUSIONS: Differences between German patients 
who initiated insulin and exenatide appear to reﬂ ect recommendations of the German 
Diabetes Association and the German health-care authorities, with exenatide favored 
when weight is high and hypoglycemia is experienced on oral therapy and HbA1c being 
only modestly raised. Treatment outcomes were consistent with results of clinical trials 
and both are important components of T2D care.
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OBJECTIVES: This analysis aimed to determine the long-term incremental difference 
in clinical outcomes for exenatide once-weekly (EQW) compared with insulin glargine. 
